Sareum Holdings PLC Sareum to Present at the ICCS 2017
June 19 2017 - 1:00AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
19 June 2017
(AIM: SAR)
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum to Present at the International Cancer Cluster Showcase
2017
Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the
specialist cancer drug discovery and development business, will
deliver a presentation at the 6th annual International Cancer
Cluster Showcase, being held today at the San Diego Convention
Center.
Dr Mitchell will be showcasing Sareum and its cancer research
pipeline as one of three companies from the UK "Golden Triangle"
biotechnology cluster.
Companies from nine North American and European innovation hubs
are scheduled to present at the event, which is organised as a
satellite to the BIO International Convention, the world's largest
gathering for the global biotech industry. Over 200 representatives
from the international oncology community are expected to
participate in this focused network meeting.
http://www.internationalcancercluster.org/
Dr Tim Mitchell, CEO of Sareum, commented: "We are delighted
that Sareum has been selected to represent British cancer research
at this prestigious event."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
The Communications Portfolio (Sareum
Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASFUFLMFWSEFM
(END) Dow Jones Newswires
June 19, 2017 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024